Elexacaftor/Tezacaftor/Ivacaftor

Red

Brand Name(s):

Indication:Cystic Fibrosis with transmembrane conductance regulator (CFTR) mutations

Rationale:1,2

Considered:Apr-21

Review Date:Apr-26

Comments:
NHS England has confirmed that ivacaftor, tezacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor will be made available as treatment options for people with cystic fibrosis who have one of an expanded range of CFTR mutations within the set criteria.

Elexacaftor/tezacaftor/ivacaftor for patients aged 12 years and above who have two F508del mutations or one F508del and a minimal function (MF) mutation.